Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

Takhzyro (Lanadelumab-flyo)

December 13, 2018 Technology Prognosis

Takhzyro (lanedelumab) is a long-acting subcutaneously administered monoclonal antibody that inhibits plasma kallikrein and, thereby, prevents overproduction of bradykinin. It is indicated for prevention of angioedema attacks in patients ≥ 12 years of age with hereditary angioedema.

GammaCore Transcutaneous Vagus Nerve Stimulator

December 6, 2018 Technology Prognosis

GammaCore is a noninvasive handheld prescription device intended to deliver transcutaneous noninvasvie vagus nerve stimulation (nVNS) for the acute treatment of pain associated with episodic cluster headache or migraine headache in adults. The FDA has also cleared the device for adjunctive use in the preventive treatment of cluster headache. The device consists of a portable stimulator with a battery, signal-generating electronics, and a digital control user interface that controls signal amplitude. Two stainless steel round discs function as skin contact surfaces. A conductive gel is applied on the stimulation surfaces of the device prior to placement on the neck. The...

Dextenza (Dexamethasone Ophthalmic Insert)

December 6, 2018 Technology Prognosis

Dextenza is a sustained-release dexamethasone hydrogel intracanalicular insert for the treatment of ocular pain after ophthalmic surgery. The insert is a rod-shaped biodegradable hydrogel intracanalicular device that delivers 0.4 mg dexamethasone in sustained and tapered release over 4 weeks. The hydrogel is conjugated with fluorescein to enable visualization through eye tissue for retention monitoring. Dextenza is inserted through the inferior punctum into the canaliculus of the operative eye following surgery. It does not require removal after therapy. The device dissolves after remaining in the eye for approximately 30 days and is cleared through the nasolacrimal duct.

Xospata (Gilteritinib) for Acute Myeloid Leukemia

December 4, 2018 Technology Prognosis

Xospata (gilteritinib; formerly ASP2215) is an oral FLT3 inhibitor indicated for the treatment of relapsed/refractory acute myeloid leukemia (AML) with an FLT3 mutation. Gilteritinib inhibits AXL, an oncogenic tyrosine kinase that is frequently overexpressed in AML; AXL facilitates FLT3 activation and has been implicated in FLT3 inhibitor resistance. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3 and AXL, as well as anaplastic lymphoma kinase (ALK). This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduction of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases....

Firdapse (Amifampridine Phosphate)

December 4, 2018 Technology Prognosis

Firdapse (amifampridine phosphate) is an oral voltage-gated potassium channel inhibitor for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.